Mumbai, India – RPG Life Sciences (BOM: 532983), a pharmaceutical company based in Mumbai, is undertaking a significant restructuring of its active pharmaceutical ingredient (API) operations. The company plans to consolidate its API business into a new, dedicated subsidiary named RPG Active Pharma. This strategic move is being supported by InvAscent, a private equity investor specializing in the healthcare sector.
The primary objective of this restructuring is to accelerate growth within the API segment. RPG Life Sciences aims to achieve this through a multifaceted approach, including pursuing acquisitions, expanding its manufacturing capabilities, and penetrating international markets. The transfer of the existing API business to the new subsidiary will be executed via a slump sale.
